NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Frontiers | Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram
Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram
VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer | 2 Minute Medicine
Survival Analysis in R
Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X
Cureus | A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience | Article
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
Median overall survival of the patients following all o | Open-i
Median overall survival according to changes in CA 19-9 | Open-i
estimation - Estimating median survival times from Kaplan-Meier plot inspection - Cross Validated
VYXEOS® Efficacy - Phase 3 Trial Data vs 7+3 | VYXEOS® (daunorubicin and cytarabine)
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with
MARGENZA® Clinical Results
Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
PADCEV® (enfortumab vedotin-ejfv) Efficacy in Patients with la/mUC
GraphPad Prism 10 Statistics Guide - Determining the median followup time
Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery
